Drs Jacob Sands and Jamie Chaft discuss the past, present, and future of perioperative management of lung cancer, including data from recent trials, disease-free survival outcomes, and changes in the standard of care.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/14736927/

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (IMpower010): A Randomized, Multicentre, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34555333/

Integration of Immunotherapy Into Adjuvant Therapy for Resected Non–Small-Cell Lung Cancer: ALCHEMIST Chemo-IO (ACCIO) https://pubmed.ncbi.nlm.nih.gov/33878954/

Pembrolizumab Versus Placebo as Adjuvant Therapy for Completely Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (PEARLS/KEYNOTE-091): An Interim Analysis of a Randomized, Triple-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36108662/

ADAURA: Phase III, Double-Blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-Stage NSCLC After Complete Surgical Resection https://pubmed.ncbi.nlm.nih.gov/29789220/

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/

Osimertinib as Adjuvant Therapy in Patients (pts) With Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC After Complete Tumor Resection: ADAURA. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA5

American Joint Committee on Cancer https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/

Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/28885881/

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non–Small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) https://www.clinicaltrials.gov/ct2/show/NCT02595944

ALINA: A Phase III Study of Alectinib Versus Chemotherapy as Adjuvant Therapy in Patients With Stage IB–IIIA Anaplastic Lymphoma Kinase-Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC). https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS8569

Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://pubmed.ncbi.nlm.nih.gov/35403841/